Clinical Report: Mesoglycan Use in Chronic Venous and Hemorrhoidal Disease
Overview
Chronic venous disease (CVD) and hemorrhoidal disease (HD) are prevalent vascular conditions that impair quality of life and impose economic burdens. Mesoglycan, a glycosaminoglycan-rich natural extract, has demonstrated beneficial effects in modifying the pathophysiological processes underlying these diseases.
Background
CVD affects up to 41% of Europeans and presents with symptoms such as leg heaviness, cramps, and varicosities, progressing to complications like ulcers. HD has a prevalence of 11–39% and shares extracellular matrix and tissue integrity alterations with CVD. Both conditions are managed conservatively initially, escalating to oral therapies and surgery if needed. Mesoglycan, containing heparan sulfate, dermatan sulfate, and other glycosaminoglycans, has been used to treat these diseases by targeting endothelial dysfunction and inflammation.
Data Highlights
Mesoglycan is composed mainly of heparan sulfate (47.5%) and dermatan sulfate (35.5%), with smaller amounts of slow-moving heparin (8.5%) and chondroitin sulfate (8.5%). CVD affects approximately 22–41% of the European population, while HD has a point prevalence of 11–39%. The glycocalyx, rich in glycosaminoglycans, plays a critical role in vascular homeostasis and is damaged in CVD, leading to inflammation and endothelial dysfunction.
Key Findings
Mesoglycan replenishes glycosaminoglycans in the endothelial glycocalyx, helping restore vascular homeostasis.
It reduces endothelial inflammation by limiting leukocyte adhesion and proinflammatory cytokine release.
It counteracts extracellular matrix degradation by modulating matrix metalloproteinase activity, preserving vein wall integrity.
Clinical use of mesoglycan in CVD and HD supports symptom relief and may slow disease progression.
Clinical Implications
Mesoglycan offers a targeted therapeutic option addressing the underlying endothelial and extracellular matrix abnormalities in CVD and HD. Its use may improve patient symptoms and quality of life by restoring glycocalyx integrity and reducing inflammation. Clinicians should consider mesoglycan as part of a stepwise management approach, especially in patients with early to moderate disease.
Conclusion
Mesoglycan's multifaceted mechanism of action supports its role in managing chronic venous and hemorrhoidal diseases by improving vascular function and tissue integrity. Further clinical studies may solidify its position in treatment algorithms.
